Hence, future strategies should involve either prior conditioning therapies to reduce the tumor burden as we did in follicular lymphoma (21) or adjuvant therapy with effective or even synergistic agents such as the IDO- and PD-L1-derived peptide vaccines in combination with nivolumab in malignant melanoma. This evidence concerns the gene IDO1 and melanoma.